Endothelial Cell Dysfunction and Increased Cardiovascular Risk in Patients With Chronic Kidney Disease
Circulation Research, vol. 132, pp. 970–992
Abstract
The endothelium is considered to be the gatekeeper of the vessel wall, maintaining and regulating vascular integrity. In patients with chronic kidney disease, protective endothelial cell functions are impaired due to the proinflammatory, prothrombotic and uremic environment caused by the decline in kidney function, adding to the increase in cardiovascular complications in this vulnerable patient population. In this review, we discuss endothelial cell functioning in healthy conditions and the contribution of endothelial cell dysfunction to cardiovascular disease. Further, we summarize the phenotypic changes of the endothelium in chronic kidney disease patients and the relation of endothelial cell dysfunction to cardiovascular risk in chronic kidney disease. We also review the mechanisms that underlie endothelial changes in chronic kidney disease and consider potential pharmacological interventions that can ameliorate endothelial health.
Authors 3
-
Constance C. F. M. J. Baaten Aachen Institute for Molecular Cardiovascular Research Constance C.F.M.J. Baaten Institute for Molecular Cardiovascular Research (IMCAR)
RWTH Aachen University · Universitätsklinikum Aachen · Maastricht University
Affiliation as printed
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands (C.C.F.M.J.B., H.N.)
Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany (C.C.F.M.J.B., S.V., H.N.)
Constance C.F.M.J. Baaten Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany (C.C.F.M.J.B., S.V., H.N.). Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands (C.C.F.M.J.B., H.N.)
-
Sonja Vondenhoff Aachen Institute for Molecular Cardiovascular Research Sonja Vondenhoff Institute for Molecular Cardiovascular Research (IMCAR)
RWTH Aachen University · Universitätsklinikum Aachen
Affiliation as printed
Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany (C.C.F.M.J.B., S.V., H.N.)
Sonja Vondenhoff Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany (C.C.F.M.J.B., S.V., H.N.)
-
RWTH Aachen University · Universitätsklinikum Aachen · Maastricht University
Affiliation as printed
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands (C.C.F.M.J.B., H.N.)
Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany (C.C.F.M.J.B., S.V., H.N.)
Cited by 245 stored of 245
Cited by patents worldwide 1 (Lens.org)
-
AVENCIGUAT FOR USE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE AND SCREENING METHOD FOR PREDICTING BENEFICIAL RESPONSE THERETOWO2025240294A1 2025-11-20 Pending